Summary of Conference Call Records Industry or Company Involved - **Li Min Co., Ltd.**: Engaged in the research, production, and sales of pesticides and veterinary drugs - **Angli Kang**: Focused on the production of innovative and generic pharmaceuticals, including pet medications Core Points and Arguments Li Min Co., Ltd. - The company is investing in a new energy project for solid-state batteries, aiming to produce 20,000 tons/year of LiFSI, which is expected to contribute an additional gross profit of 600-800 million yuan [3][4] - The company is collaborating with Chengdu Green Xinnuo and Shanghai Zhisheng Yougu to develop RNA and small peptide biopesticides, enhancing its synthetic biology capabilities [3] - The demand for the company's products is anticipated to increase due to the supply tightness of chlorantraniliprole, which overlaps with its existing products [3] - The company has signed a cooperation agreement with a technical team led by Professor Guan Shiyou, focusing on the full chain technology of new energy electrolytes [3] Angli Kang - The company is involved in the production of chemical raw materials, chemical formulations, and veterinary drugs, with a focus on various therapeutic areas including anti-infectives and cardiovascular drugs [5] - Angli Kang has a pipeline of approximately 50 new generic drug varieties expected to be launched, supported by significant R&D investments over the past few years [5] - The company is shifting its R&D strategy towards modified new drugs and innovative drugs, particularly in the areas of cardiovascular and pain management [5] - The pet medication project initiated in 2021 targets various health issues in pets, including pain, colds, and digestive problems [5] Other Important but Possibly Overlooked Content - The overall market showed a mixed performance with the ChiNext index leading the gains, while the Shanghai Composite Index managed to stay above 3400 points [1] - Institutional participation decreased slightly, with 17 stocks having net buy/sell amounts exceeding 10 million yuan, indicating a cautious market sentiment [2] - The performance of various sectors was noted, with rare earth permanent magnet stocks and automotive parts showing strong gains, while nuclear power stocks faced adjustments [1] - The projected increase in LiFSI usage in new battery technologies, particularly in the 4680 battery, is expected to drive demand significantly, with estimates suggesting a potential increase in usage from 0.5-2% to as high as 15% [4]

6月11日沪指上涨0.52%，盘后龙虎榜数据显示，机构现身23只个股龙虎榜，净买入7只，净卖出16只。 深沪股通席位出现在8只个股龙虎榜。 证券时报·数据宝统计显示，6月11日机构专用席位现身23只个股龙虎榜，合计净卖出1.76亿元。个股来 看，净买入7只，净卖出16只。 机构龙虎榜净买卖个股 深沪股通现身8股龙虎榜 机构专用席位净买入金额最多的是昂利康，该股今日收盘涨停，全天换手率为29.07%，成交额为13.93 亿元。因日涨幅偏离值达9.29%上榜龙虎榜，前五大买卖营业部中有6家机构专用席位，为买一、买 二、买三、买四、卖一、卖五，合计净买入17011.88万元。 利民股份，今日收盘涨停，全天换手率为24.92%，成交额为20.51亿元。因日涨幅偏离值达9.29%上榜龙 虎榜，前五大买卖营业部中有5家机构专用席位，为买一、买二、买五、卖一、卖五，合计净买入 10508.48万元。 中超控股，因日换手率达35.73%、日跌幅偏离值达-10.71%上榜龙虎榜，前五大买卖营业部中有3家机构 专用席位，为买二、卖二、卖三，合计净卖出6044.18万元。 6月11日机构龙虎榜净买卖个股 | 代码 | 简称 | 当 ...

沪指6月11日上涨0.52%，申万所属行业中，今日上涨的有28个，涨幅居前的行业为有色金属、农林牧 渔，涨幅分别为2.21%、2.02%。基础化工行业今日上涨0.23%。跌幅居前的行业为医药生物、通信、美 容护理，跌幅分别为0.41%、0.28%、0.10%。 资金面上看，两市主力资金全天净流入15.06亿元，今日有14个行业主力资金净流入，非银金融行业主 力资金净流入规模居首，该行业今日上涨1.90%，全天净流入资金44.69亿元，其次是汽车行业，日涨幅 为1.70%，净流入资金为27.50亿元。 主力资金净流出的行业有17个，医药生物行业主力资金净流出规模居首，全天净流出资金26.29亿元， 其次是基础化工行业，净流出资金为19.09亿元，净流出资金较多的还有通信、电力设备、银行等行 业。 基础化工行业资金流出榜 | 代码 | 简称 | 今日涨跌幅（%） | 今日换手率（%） | 主力资金流量（万元） | | --- | --- | --- | --- | --- | | 002250 | 联化科技 | -10.00 | 24.36 | -88639.26 | | 300796 | 贝斯美 | -7.92 ...

利民股份6月11日交易公开信息 | 买/ | 会员营业部名称 | 买入金额（万元） | 卖出金额（万元） | | --- | --- | --- | --- | | 卖 | | | | | 买一 | 机构专用 | 7380.42 | 1928.35 | | 买二 | 机构专用 | 7182.85 | 3856.62 | | 买三 | 国泰海通证券股份有限公司宜昌沿江大道证券营业部 | 4189.79 | 1.49 | | 买四 | 华福证券有限责任公司成都东大路证券营业部 | 3150.31 | 3.08 | | 买五 | 机构专用 | 2877.93 | 1147.75 | | 卖一 | 机构专用 | 7182.85 | 3856.62 | | 卖二 | 东方财富证券股份有限公司拉萨团结路第一证券营业 | 1624.64 | 2114.44 | | | 部 | | | | 卖三 | 东方财富证券股份有限公司拉萨东环路第二证券营业 | 1719.53 | 1966.75 | | | 部 | | | | 卖四 | 国信证券股份有限公司浙江互联网分公司 | 1446.83 | 1958.45 | | 卖五 | 机 ...

6月11日，上证指数上涨0.52%，深证成指上涨0.83%，创业板指上涨1.21%。盘后龙虎榜数据显示，共 有51只个股因当日异动登上龙虎榜，资金净流入最多的是利民股份（002734.SZ），达1.66亿元。 据21投资通智能监测，24只个股龙虎榜出现了机构的身影，北向资金参与龙虎榜中的个股共涉及8只。 1.66亿资金抢筹利民股份，2.89亿资金出逃联化科技 51只上榜的龙虎榜个股中，23只个股被净买入，28只个股被净卖出。其中，资金净买入最多的是利民股 份，达1.66亿元，占总成交金额的8.09%。利民股份当日收盘上涨10.02%，换手率为24.92%。 | 名称 | 涨跌幅 | 戊席榜净买 | 净买额占 | 换手率 | 解读 | | --- | --- | --- | --- | --- | --- | | | | 额(万元 | 息成交比 | | | | 利民股份 | 10.02% | 16595 | 8.09% | 24.92% | 3家机构买入,成功 率42.25% | | 楚天龙 | 10.03% | 14924 | 6.32% | 28.22% | 买一主买,成功率3 | | | | | | | ...

Group 1: Market Overview - The total trading volume in the Shanghai and Shenzhen markets reached 1.26 trillion yuan, a decrease of 159.9 billion yuan compared to the previous trading day [2] - Sectors such as rare earth permanent magnets, gaming, automotive parts, and securities saw significant gains, while sectors like controllable nuclear fusion, biological vaccines, communication services, and beverage manufacturing experienced declines [2] Group 2: Notable Stocks - Yiming Pharmaceutical (002826) achieved a limit-up of 9.99%, marking its sixth consecutive trading day of gains, driven by a change in control and diabetes generic drugs [1][2] - Wukuyatu (002878) rose by 9.98%, with a total of five gains over nine days, attributed to digital cultural assets and IP culture [1][2] - Aonlikang (002940) also increased by 9.98%, with seven gains over the past seven days, focusing on innovative drugs and generics [1][2] - Jinying Co. (600232) hit a limit-up of 10.00%, supported by injection molding machines, textile machinery, and lithium batteries, achieving four consecutive gains [1][2] - Chutianlong (003040) saw a limit-up of 10.03%, driven by digital RMB and cross-border payments, with three gains over four days [1][2] Group 3: Institutional Activity - The top three net purchases on the Dragon and Tiger list were from Limin Co. (002734), Chutianlong (003040), and Aonlikang (002940), with net purchases of 166 million yuan, 149 million yuan, and 91.69 million yuan respectively [4] - The top three net sales were from Lianhua Technology (002250), Baili Electric (600468), and Zhi De Co. (603333), with net sales of 289 million yuan, 209 million yuan, and 169 million yuan respectively [5] Group 4: Company Highlights - Limin Co. reported a revenue of 1.211 billion yuan for Q1 2025, a year-on-year increase of 22.28%, with a net profit of 108 million yuan, marking a turnaround due to strong demand and price increases [10] - Aonlikang focuses on innovative drugs and generics, with a recent trading volume of 1.393 billion yuan and a net institutional purchase of 235 million yuan [11][15] - Chutianlong is actively developing a digital RMB smart contract platform, collaborating with multiple organizations to provide integrated solutions for various scenarios [18]

Group 1 - Institutional investors bought a total of 30 stocks, with net purchases in 9 stocks and net sales in 21 stocks on the day [1] - The top three stocks with the highest institutional purchases were: Limin Co., Ltd. (¥193 million), Anglikang (¥170 million over three days), and Aoyang Health (¥13.56 million) [1] - Limin Co., Ltd. saw a net purchase of ¥193 million from 5 institutions, benefiting from rising prices of key products such as Abamectin and Mancozeb, which is expected to enhance its profitability [3] Group 2 - The stock of Limin Co., Ltd. increased by 10.02% with 3 buyers and 2 sellers [2] - Anglikang's stock rose by 9.98% with 4 buyers and 2 sellers [2] - The automotive industry is experiencing a shift as major companies have committed to standardizing supplier payment terms to 60 days, which may alleviate profit pressures across the industry [3]

这几只票暗盘资金正在偷偷流入，立即查看>> 利民股份（002734）今日涨停，成交额20.51亿元，换手率24.92%，盘后龙虎榜数据显示，三机构专用 席位净买入1.05亿元。 ...

Core Viewpoint - ST Hongtai announced a price adjustment for its 97% chlorantraniliprole product to 300,000 yuan per ton, a more than 40% increase compared to last year's low of 210,000 yuan per ton, primarily due to limited upstream raw material supply and rising costs [1][3]. Industry Overview - Chlorantraniliprole is the world's largest insecticide, with annual global sales exceeding $2 billion. After the expiration of its compound patent in China in August 2022, market prices continued to decline, with a cumulative drop of 34.38% in 2024. However, since 2025, prices have rebounded due to low effective capacity release influenced by intermediates and operating rates, rising to 228,000 yuan per ton on May 25, an increase of 8.57% [3]. - Currently, there are over 100,000 tons per year of chlorantraniliprole production capacity under construction or planning in China, but the progress of planned capacity construction has slowed due to the impact of intermediate K amine supply and declining raw material prices [3]. Market Reaction - Following the price adjustment announcement, the pesticide sector continued to show strength on June 9, with stocks such as Changqing Co. and Guangkang Biochemical hitting historical highs, and ST Hongtai and other stocks also rising [3]. - Analysts generally believe that chlorantraniliprole prices are likely to experience a phase of upward momentum. Future project approvals and production regulations involving hazardous chemical reactions such as nitration and chlorination are expected to become stricter, benefiting leading companies in the chemical industry that can maintain stable production of existing products [3]. Company Responses - Due to changes in market supply dynamics, investor interest in companies involved in chlorantraniliprole has increased, prompting several listed companies to respond. Lianhua Technology stated that it provides advanced intermediates through a CDMO model and does not directly produce the product, indicating limited overall impact on the company. Huailong Co. is steadily advancing its chlorantraniliprole raw material and intermediate project with an annual output of 2,000 tons. Lier Chemical is orderly constructing a 5,000 tons/year production facility. Changqing Co. confirmed that its insecticides are currently in normal production. Liming Co. noted that if chlorantraniliprole supply tightens, it would boost demand for alternatives such as abamectin and methomyl [4].

Core Viewpoint - The price of 97% chlorantraniliprole has been adjusted to 300,000 yuan/ton due to limited supply of upstream raw materials, marking an increase of over 40% compared to the low point of 210,000 yuan/ton last year. This price adjustment is expected to lead to a phase of price increase in the market for chlorantraniliprole [1][2]. Industry Summary - Chlorantraniliprole has a global annual sales exceeding $2 billion, making it the largest insecticide worldwide. It was discovered by the former DuPont company in 2000 and was first launched in 2008. The expiration of its compound patent in China on August 13, 2022, significantly changed the market landscape [2]. - Following the patent expiration, the market price of chlorantraniliprole continued to decline, with a cumulative drop of 34.38% from 320,000 yuan/ton at the beginning of 2024 to 210,000 yuan/ton by the end of the year. However, since 2025, prices have rebounded from 210,000 yuan/ton to 228,000 yuan/ton as of May 25, 2025, reflecting an increase of 8.57% [2]. - Currently, over 100,000 tons/year of chlorantraniliprole production capacity is under construction or planned in China. However, actual progress has been hindered by the supply of intermediates and the continuous decline in raw material prices [2]. Company Responses - Lianhua Technology announced that it provides advanced intermediates for chlorantraniliprole through a CDMO business model and does not directly produce chlorantraniliprole. The company has a long-term partnership with its client and has not received any notifications regarding increased demand for related products [3]. - Huayong Co. stated that it has an annual production capacity of 2,000 tons of chlorantraniliprole and intermediates, with steady progress in project construction [3]. - Lier Chemical expressed optimism about the market prospects for chlorantraniliprole and is currently constructing a production facility with a capacity of 5,000 tons/year [3]. - Liming Co. indicated that its products cover various categories of insecticides, and if chlorantraniliprole supply tightens, it may boost the demand for its widely used insecticides, such as abamectin and methomyl, which have overlapping efficacy with chlorantraniliprole [4]. - Industry insiders noted that if the price of chlorantraniliprole rises sharply in the short term, downstream users may opt for alternative insecticides, increasing the demand for substitutes [4].